Navigation Links
SuperStim Pediatric EMG

ProductsSuperStim Pediatric EMG
Company Xltek
Item SuperStim Pediatric EMG
Features Greatly enhanced pediatric settings

We understand your needs because we listen. The XLTEK SuperStim has been specifically designed for pediatric studies. The SuperStims advanced settings give you independent control of both the amplitude and duration of each individual negative or positive stimulus pulse, not just tandem control of those of the combined pulse.

Flexibility in the key

How you deliver stimulation is up to you. With XLTEKs SuperStim, you can direct stimulation from either its dedicated front panel or via USB connectivity.

Description Combining exceptional new features and state-of-the art design, XLTEKs latest innovation, the SuperStim brain stimulator, delivers biphasic intracranial stimulation up to 30 mA and 300 volts and transcranial stimulation up to 1 ampere and 1500 volts.
Info Xltek
Customer Service: (800) 387 7516
Web site: http://www.xltek.com

Related medicine products :

1. McNeil-Goldman Scleral and Blepharostat Ring - Pediatric
2. Cook Eye Speculum - Pediatric
3. Kratz-Barraquer Eye Speculum - Pediatric
4. Barraquer Pediatric Speculum - Solid Blade
5. Barraquer Pediatric Speculum - Wire Blade
6. Barraquer Eye Speculum - Pediatric
7. Pediatric Ostrum Antrum Punch Forceps
8. Pediatric Rotating Ostrum Antrum Punch Forceps
9. Pediatric Combination Eye Garter Shield Cover and Fox Shield
10. Pediatric Corneal Shields 10/Box
11. Ishihara Test Unlettered Pediatric 10 Plate Book
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 1AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 2AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 1Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 2Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 4Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 5